Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis

Abstract

In this cohort study, rituximab treatment was associated with significantly improved skin and lung fibrosis in SSc in a long-term follow-up. Decrease in serum immunoglobulins was associated with greater clinical response.